Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis

Figure 1 Improvements in liver histology at week 240 of entecavir treatment in patients (n = 38) with paired liver biopsies (baseline and week 240). A: Distribution of Knodell necroinflammatory scores at baseline and at week 240; B: Distribution of Ishak fibrosis scores at baseline and at week 240.

Figure 2 Relationship between hepatitis B virus DNA level and histologic improvement. A: Relationships between hepatitis B virus (HBV) DNA level and Knodell histologic activity index and Ishak fibrosis score at baseline; B: Relationships between changes from baseline in HBV DNA level and Knodell histologic activity index and Ishak fibrosis score at week 240 of entecavir treatment.

Figure 3 Proportion of patients with disease progression in compensated and decompensated cirrhosis groups.

Figure 4 Improvements in Child-Pugh grade at weeks 96 and 240 of entecavir treatment in patients with compensated and decompensated cirrhosis.